Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation

NCT ID: NCT02404467

Last Updated: 2020-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

502 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis behind this study is that there is a proportion of patients considered high or intermediate risk for surgery, but relatively low risk for TAVI, which can be discharged early after the procedure (within the first 2-3 days) without additional risks. Therefore, when performed in safety, an early discharge may cut periprocedural TAVI costs significantly.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TAVI (Transcatheter aortic valve Implantation) - A viable alternative to surgical aortic valve replacement for patients with severe symptomatic aortic stenosis.

Considered as being at unacceptable surgical risk. Despite its widespread utilization, there are procedure specific complications and hospitalization associated costs that limit TAVI expansion into patient populations with lower risk.

Cost-effectiveness of TAVI has been investigated either compared with standard therapy for patients who are not candidates for surgical valve replacement or with conventional surgical replacement in high-risk patients.

Formal economic evaluation in inoperable patients demonstrated that the benefits of TAVI were achieved at an acceptable incremental cost to society, at least in the context of the U.S. and U.K. health systems.

In patients with severe, symptomatic AS who are at high but not prohibitive surgical risk, the PARTNER A trial demonstrated that TAVI appeared to be an economically attractive strategy compared with aortic valve replacement, provided that patients are suitable for a transfemoral approach. On the other hand, results for trans-apical TAVI compared with surgical replacement were economically unfavorable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients receiving transfermoral TAVI

TF TAVI

TF TAVI

Intervention Type DEVICE

Follow-up Observation of patients having received a TF-TAVI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TF TAVI

Follow-up Observation of patients having received a TF-TAVI

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* None

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role collaborator

Institut für Pharmakologie und Präventive Medizin

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Corrado Tamburino, MD

Role: PRINCIPAL_INVESTIGATOR

Ferrarotto Hospital, University of Catania

Marco Barbanti, MD

Role: PRINCIPAL_INVESTIGATOR

Ferrarotto Hospital, University of Catania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Montevergine Clinic

Mercogliano, AV, Italy

Site Status

Ferrarotto Hospital, University of Catania

Catania, Sicily, Italy

Site Status

Universita degli studi di Bari Aldo Moro

Bari, , Italy

Site Status

University Hospital of Bologna, Policlinico S. Orsola-Malpighi (Pad.23)

Bologna, , Italy

Site Status

Clinica San Gaudenzio di Novara

Novara, , Italy

Site Status

AMC - Academic Medical Center - University of Amsterdam

Amsterdam, AZ, Netherlands

Site Status

LUMC - Leiden University Medical Center

Leiden, , Netherlands

Site Status

Royal Vicotria Hospital, Belfast Trust

Belfast, , United Kingdom

Site Status

Papworth Hospital

Cambridge, , United Kingdom

Site Status

James Cook Hospital

Middlesbrough, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy Netherlands United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Barbanti M, Baan J, Spence MS, Iacovelli F, Martinelli GL, Saia F, Bortone AS, van der Kley F, Muir DF, Densem CG, Vis M, van Mourik MS, Seilerova L, Luske CM, Bramlage P, Tamburino C. Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation - rationale and design of the FAST-TAVI registry. BMC Cardiovasc Disord. 2017 Oct 10;17(1):259. doi: 10.1186/s12872-017-0693-0.

Reference Type BACKGROUND
PMID: 29017461 (View on PubMed)

Barbanti M, van Mourik MS, Spence MS, Iacovelli F, Martinelli GL, Muir DF, Saia F, Bortone AS, Densem CG, van der Kley F, Bramlage P, Vis M, Tamburino C. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention. 2019 Jun 20;15(2):147-154. doi: 10.4244/EIJ-D-18-01197.

Reference Type RESULT
PMID: 30777842 (View on PubMed)

Spence MS, Baan J, Iacovelli F, Martinelli GL, Muir DF, Saia F, Bortone AS, Densem CG, Owens CG, van der Kley F, Vis M, van Mourik MS, Costa G, Sykorova L, Luske CM, Deutsch C, Kurucova J, Thoenes M, Bramlage P, Tamburino C, Barbanti M. Prespecified Risk Criteria Facilitate Adequate Discharge and Long-Term Outcomes After Transfemoral Transcatheter Aortic Valve Implantation. J Am Heart Assoc. 2020 Aug 4;9(15):e016990. doi: 10.1161/JAHA.120.016990. Epub 2020 Jul 25.

Reference Type RESULT
PMID: 32715844 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://fast-tavi.s4trials-europe.net

registry on-line eCRF website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FAST-TAVI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.